Terms: = Cervical cancer AND KIT, C-Kit, 3815, ENSG00000157404, CD117, SCFR, P10721 AND Staging
6 results:
1. CircAGFG1 aggravates the progression of cervical cancer by downregulating p53.
Wang XH; Li J
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(4):1704-1711. PubMed ID: 32141537
[TBL] [Abstract] [Full Text] [Related]
2. LncRNA FOXD2-AS1 accelerates the progression of cervical cancer via downregulating CDX1.
Chen DZ; Wang TF; Dai WC; Xu X; Chen PF
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10234-10240. PubMed ID: 31841177
[TBL] [Abstract] [Full Text] [Related]
3. Upregulation of LncRNA PANDAR predicts poor prognosis and promotes cell proliferation in cervical cancer.
Huang HW; Xie H; Ma X; Zhao F; Gao Y
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4529-4535. PubMed ID: 29131264
[TBL] [Abstract] [Full Text] [Related]
4. [Bcl-2 associated athanogene 3 affects the epithelial-mesenchymal transition in human cervical cancer].
Wei L; Qin XP; Zhao XX; Wang W
Zhonghua Fu Chan Ke Za Zhi; 2017 Aug; 52(8):551-557. PubMed ID: 28851173
[No Abstract] [Full Text] [Related]
5. [Activity of the National Oncology R&D Consortium in 2004].
Tímár J;
Magy Onkol; 2005; 49(1):3-7. PubMed ID: 15902326
[TBL] [Abstract] [Full Text] [Related]
6. [Basic evaluation of measurement of the serum level of squamous cell carcinoma-related antigen (SCC) and its value following irradiation of cancer of the uterine cervix].
Obata Y; Tadokoro M; Kazato S; Nishi H; Ito M; Shibata H; Mizuno K; Kawamura N; Yamaguchi T; Yoshizumi T
Gan No Rinsho; 1987 Jan; 33(1):60-4. PubMed ID: 3820601
[TBL] [Abstract] [Full Text] [Related]
